Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274651 · ClinicalTrials.gov registry record · Phase 2
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase 2 study, sponsored by Valerio Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00274651 is a Phase 2 study that was terminated before completion, run by Valerio Therapeutics. The registered enrollment target is 53 participants.
The verdict
NCT00274651, a Phase 2 study, was terminated before completion, sponsored by Valerio Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.
Interventions
- DRUG belinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274651
The ClinicalTrials.gov registry entry for NCT00274651 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valerio Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which belinostat is the first listed.
NCT00274651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274651 about?
NCT00274651 is a clinical study titled "A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas". Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1...
What is the current status of trial NCT00274651?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2006-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00274651?
The interventions under investigation include: belinostat (DRUG).
Who is sponsoring clinical trial NCT00274651?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.